Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / South Dakota

Peptide legality · South Dakota · updated 2026-09-21

Are peptides legal in South Dakota?

Gray area

Peptides sit in a gray zone in South Dakota, where prescription and pharmacy pathways are legal but many popular peptides lack a clear compounding home and gray-market sales are not.

Legal status overview

Peptides occupy a gray zone in South Dakota. The state has not enacted a peptide-specific ban or a compounding standard stricter than the federal floor, so what is permitted turns almost entirely on federal law layered over routine South Dakota Board of Pharmacy oversight of the roughly 10 traditional 503A pharmacies operating in the state. FDA-approved peptide medicines remain legal by prescription, and patient-specific compounding is allowed when it meets federal criteria, but substances such as BPC-157 and TB-500 have no clear compounding status and research-chemical sales for human use are not lawful. The practical line is who prescribes and where the product is sourced, not the word peptide itself.

Key points

  • South Dakota has not passed a peptide-specific statute or a compounding rule tougher than the federal baseline, so peptide legality in the state tracks federal FD&C Act Sections 503A and 503B applied by the South Dakota Board of Pharmacy. [6]
  • The state hosts an estimated 10 traditional 503A compounding pharmacies and no FDA-registered 503B outsourcing facilities, and no compounding-related FDA warning letters were issued to South Dakota addresses over the prior 24 months. [5]
  • On April 15, 2026 the FDA removed BPC-157 and several other peptides from Category 2 of the 503A bulks list, but did not move them to Category 1, leaving them ineligible for affirmative clearance to compound. [3]
  • A compounded peptide is a preparation that is not FDA-approved; not a generic; not evaluated by the FDA, which is legally distinct from an approved commercial drug. [2]
  • After the FDA declared the GLP-1 shortage resolved in early 2025, compounding of drugs like semaglutide is limited to documented patient-specific clinical need rather than routine mass production. [4]
  • Human growth hormone (somatropin) carries a separate federal restriction: distributing it for any use other than an FDA-recognized indication under a valid prescription is a federal crime under 21 U.S.C. 333(e). [7]
  • Only a licensed prescriber plus a licensed compounding pharmacy creates a lawful path for a non-commercial peptide; buying research-labeled peptides for human use falls outside that framework. [1]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and holds no USP monograph. Removed from 503A Category 2 in April 2026 but not placed in Category 1, so it has no affirmative compounding clearance in South Dakota.
GLP-1 class (Wegovy® (semaglutide), Zepbound® (tirzepatide))
Legal
The FDA-approved brand products are legal by prescription. Compounded versions are not FDA-approved; not a generic; not evaluated by the FDA and are limited to documented patient-specific need after the shortage ended.
TB-500 (thymosin beta-4 fragment)
Gray area
Not FDA-approved. Removed from Category 2 in April 2026 without Category 1 placement, so no lawful compounding pathway is established. Prohibited in sport by WADA.
Growth hormone / somatropin
Restricted
FDA-approved for defined deficiency and wasting indications by prescription only. Distribution for anti-aging, bodybuilding, or athletic use is prohibited under 21 U.S.C. 333(e) even with a prescription.

Frequently asked questions

Are peptides legal in South Dakota?

It depends on the peptide and the source. FDA-approved peptide medicines are legal by prescription, and patient-specific compounding is allowed when it meets federal rules, but many popular research peptides have no clear legal compounding status and are not sold lawfully for human use. This is information, not legal or medical advice.

Can I get BPC-157 from a compounding pharmacy in South Dakota?

BPC-157 is not FDA-approved and, after its April 2026 removal from Category 2, was not added to Category 1, so it has no affirmative federal clearance for compounding. Availability is uncertain and depends on evolving FDA action and pharmacy policy.

Is compounded semaglutide still available in South Dakota?

Compounded semaglutide is not FDA-approved; not a generic; not evaluated by the FDA. Since the FDA declared the shortage over, it may be compounded only for a documented patient-specific clinical reason, not as a routine substitute for the brand product.

Does South Dakota have its own peptide law?

South Dakota has not enacted a peptide-specific statute or a compounding standard stricter than federal law. Oversight comes from the South Dakota Board of Pharmacy applying the federal FD&C Act framework.

Is human growth hormone legal in South Dakota?

Somatropin is FDA-approved for specific medical indications by prescription. Distributing it for anti-aging, bodybuilding, or athletic performance is a federal crime under 21 U.S.C. 333(e), regardless of a prescription.

General information based on the sourced research above, not legal advice. For a specific situation in South Dakota, consult a licensed attorney familiar with pharmaceutical law.